Bristol Myers Stock Rises 16% in 3 Months: Buy, Sell or Hold?

Bristol Myers Squibb Company (BMY) is experiencing a good run of late after touching a 52-week low of $39.35 on July 5. This short rally has given anxious investors a ray of hope. The biotech giant has been facing a few challenges for quite some time now.Shares of BMY have risen 16.2% in the past three months compared with the industry’s growth of 3.8%. The stock has also outperformed the sector and the S&P 500 during this time frame.Much of this outperformance can be attributed to the company’s better-than ...